Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.

There are currently, however, two radioligands that are United States Food and Drug Administration (FDA)-approved for the treatment of mCRPC patients: Patients with advanced prostate cancer are at ...

Medically reviewed by Aleesha Grier, PsyD Metastatic breast cancer affects people in many ways. The symptoms experienced by ...

A recent study has uncovered the molecular mechanisms behind osteocyte death in melanoma bone metastasis, revealing that ferroptosis—an iron-dependent form of cell death—plays a central role in the ...

Follicular thyroid cancer with bone involvement was associated with a significantly elevated risk for brain metastases among women.

Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ ...

New innovative local treatment for osteolytic bone disease in multiple myeloma Date: January 14, 2025 Source: Vrije Universiteit Brussel Summary: A team of researchers has developed a new ...

The rising incidence of metastatic breast cancer (MBC) among young Indian women highlights the need for personalised care. Understanding treatment options, empowering decision-making, ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial ... of skeletal-related events (SREs) in bone metastatic CRPC (mCRPC). Denosumab compared with ...